Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies
- PMID: 39399864
- PMCID: PMC11471058
- DOI: 10.1016/j.lanwpc.2024.101183
Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies
Erratum in
-
Corrigendum to "Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies" [The Lancet Regional Health-Western Pacific, Volume 50, September 2024, 101183].Lancet Reg Health West Pac. 2024 Nov 21;52:101249. doi: 10.1016/j.lanwpc.2024.101249. eCollection 2024 Nov. Lancet Reg Health West Pac. 2024. PMID: 39640540 Free PMC article.
Abstract
Here we first review the limited available literature addressing the current landscape of specialist assessment services for dementia and cognitive decline and the preparedness for new amyloid-targeting therapies for Alzheimer's disease across the Western Pacific region. Considering the scarcity of literature, as national representatives of Western Pacific nations we were then guided by the World Health Organization's Global Action Plan on Dementia to provide country-specific reviews. As a whole, we highlight that the existing diverse socioeconomic and cultural landscape across the region poses unique challenges, including varying access to services and marked differences among countries in their preparedness for upcoming amyloid-targeting therapies for Alzheimer's disease. Therefore, there is an urgent call for intergovernmental collaboration and investment across the Western Pacific to ensure that for all nations, citizens living with dementia and cognitive decline have access to effective and equitable methods of diagnosis, treatment and care.
Keywords: Alzheimer's disease; Amyloid-targeting therapies; Dementia; Memory clinics.
© 2024 The Author(s).
Conflict of interest statement
VMA is on the advisory board of Hi- Eisai Philippines and Torrent Philippines and has received lecture honoraria from Medichem Philippines, Natrapharm, Kusum Healthcare, Hi-Eisai Philippines and Lundbeck Philippines. CC is on the advisory boards of Cerboriva, Cerecin, Eisai, Lundbeck and Moleac. MCP is on the advisory boards of Eisai, and Lilly. MPT has received honoraria from Sanofi, Merck, Glaxo-Smith-Kline, Menarini, Pfizer, Novartis, Boehringer Ingelheim, Abbott as a speaker and advisory board member. SLN has recived honoraria from Nutrica, a travel grant from the International Neuropsychological Society and is on an advisory board for Eisai Australia.
Figures
Similar articles
-
Corrigendum to "Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies" [The Lancet Regional Health-Western Pacific, Volume 50, September 2024, 101183].Lancet Reg Health West Pac. 2024 Nov 21;52:101249. doi: 10.1016/j.lanwpc.2024.101249. eCollection 2024 Nov. Lancet Reg Health West Pac. 2024. PMID: 39640540 Free PMC article.
-
Regional health priorities for dementia: a roadmap for the Western Pacific.Lancet Reg Health West Pac. 2024 Sep 16;50:101179. doi: 10.1016/j.lanwpc.2024.101179. eCollection 2024 Sep. Lancet Reg Health West Pac. 2024. PMID: 39399866 Free PMC article. Review.
-
Anti-Amyloid Therapies for Alzheimer's Disease: An Alzheimer Europe Position Paper and Call to Action.J Prev Alzheimers Dis. 2024;11(2):265-273. doi: 10.14283/jpad.2024.37. J Prev Alzheimers Dis. 2024. PMID: 38374732
-
The 2023 Latin America report of the Lancet Countdown on health and climate change: the imperative for health-centred climate-resilient development.Lancet Reg Health Am. 2024 Apr 23;33:100746. doi: 10.1016/j.lana.2024.100746. eCollection 2024 May. Lancet Reg Health Am. 2024. PMID: 38800647 Free PMC article. Review.
-
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.Lancet Neurol. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5. Lancet Neurol. 2020. PMID: 32333900
Cited by
-
WHO's iSupport model for dementia care: why the mode and measures matter.Lancet Reg Health Eur. 2024 Nov 21;48:101144. doi: 10.1016/j.lanepe.2024.101144. eCollection 2025 Jan. Lancet Reg Health Eur. 2024. PMID: 39634278 Free PMC article. No abstract available.
-
Validity and reliability of the Approaches to Dementia Questionnaire (ADQ) in Indonesian health students.BMC Med Educ. 2025 May 29;25(1):798. doi: 10.1186/s12909-025-07332-2. BMC Med Educ. 2025. PMID: 40442706 Free PMC article.
-
The patient pathway for mild cognitive impairment due to Alzheimer's disease in Asia: Current practices, barriers, and expert recommendations for optimization.J Prev Alzheimers Dis. 2025 Aug;12(7):100215. doi: 10.1016/j.tjpad.2025.100215. Epub 2025 Jun 6. J Prev Alzheimers Dis. 2025. PMID: 40483260 Free PMC article.
-
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.Alzheimers Dement. 2025 Aug;21(8):e70536. doi: 10.1002/alz.70536. Alzheimers Dement. 2025. PMID: 40760693 Free PMC article. Review.
References
-
- World Health Organization . 2017. Global action plan on the public health response to dementia 2017–2025.
-
- From Plan to Impact V: WHO global action plan: the time to act is now. 2022. https://www.alzint.org/resource/from-plan-to-impact-v/
-
- Population clock: world. https://www.census.gov/popclock/world
-
- World population ageing 2019: highlights New York city United Nations, department of economic and social affairs, population division. https://www.un.org/en/development/desa/population/publications/pdf/agein...
-
- Miksa B. World Economic Forum; Cologny: 2015. What are the economic consequences of rapidly ageing populations.https://www.weforum.org/agenda/2015/08/what-are-the-economic-consequence...
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous